At least six biotechs and pharmas reported earnings last week. Sales of new products helped big pharmas Johnson & Johnson (NYSE:JNJ) and Roche (SIX:ROG; OTCQX:RHHBY) beat the Street's revenue estimates. For instance, J&J reported a 73% increase in sales of Zytiga abiraterone to $464 million in 3Q13. The drug was approved for metastatic castration-resistant prostate cancer (CRPC) in the U.S. and EU in 2011. The label was expanded to chemotherapy-naïve patients in the U.S. in 2012 and in the EU earlier this year. J&J added $6.1 billion to its market cap last week. In its 3Q13 update, Roche CEO Severin Schwan highlighted uptake of breast cancer drugs Perjeta pertuzumab and Kadcyla ado-trastuzumab emtansine. Perjeta sales in 3Q were CHF78 million ($86 million), while sales of Kadcyla were CHF73 million ($80 million). Perjeta was launched in the U.S. in 2012 and in the EU in March, and Kadcyla was launched in the U.S. in February. Kadcyla uses antibody-drug conjugate technology from ImmunoGen Inc. (NASDAQ:IMGN). Roche added $2.8 billion to its market cap last week, while shares of ImmunoGen were up 4% on the week. Abbott Laboratories (NYSE:ABT) tacked on